These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 23286859

  • 1. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV.
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [Abstract] [Full Text] [Related]

  • 2. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
    Papatheodoridis GV.
    Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
    [Abstract] [Full Text] [Related]

  • 3. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H, Jia J.
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [Abstract] [Full Text] [Related]

  • 4. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Buti M.
    Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
    [Abstract] [Full Text] [Related]

  • 5. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G.
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [Abstract] [Full Text] [Related]

  • 6. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group.
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [Abstract] [Full Text] [Related]

  • 7. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL.
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [Abstract] [Full Text] [Related]

  • 8. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Vlachogiannakos J, Papatheodoridis GV.
    Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
    [Abstract] [Full Text] [Related]

  • 9. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M, Mangia G, Lampertico P.
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [Abstract] [Full Text] [Related]

  • 10. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J, Papatheodoridis GV.
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [Abstract] [Full Text] [Related]

  • 11. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF, Lai CL.
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [Abstract] [Full Text] [Related]

  • 12. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P, Viganò M, Colombo M.
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [Abstract] [Full Text] [Related]

  • 13. Current developments in nucleoside/nucleotide analogues for hepatitis B.
    Lo AO, Wong GL.
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):607-22. PubMed ID: 24787673
    [Abstract] [Full Text] [Related]

  • 14. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH, Schalm SW, Janssen HL.
    Best Pract Res Clin Gastroenterol; 2008 Aug; 22(6):1093-108. PubMed ID: 19187869
    [Abstract] [Full Text] [Related]

  • 15. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH.
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [Abstract] [Full Text] [Related]

  • 16. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Di Perri G.
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [Abstract] [Full Text] [Related]

  • 17. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL, Netherlands Association of Gastroenterologists and Hepatologists.
    Neth J Med; 2008 Apr; 66(7):292-306. PubMed ID: 18663260
    [Abstract] [Full Text] [Related]

  • 18. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C.
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH.
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [Abstract] [Full Text] [Related]

  • 20. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M, Invernizzi F, Lampertico P.
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.